Canurta Therapeutics

Our story began with a breakthrough. In 2019, Canurta Advisor Dr. Tariq Akhtar’s lab at the University of Guelph developed a patented method to efficiently extract and enrich rare polyphenols like cannflavins A & B.

At @TOtechweek we’ll examine how biohacking and AI health innovations can build the capacities machines cannot replicate: presence, creativity, discernment, leadership under pressure, and the ability to connect through leisure and shared experience luma.com/dbt71yy1

#SOVEREIGNTY is the defining question of our time: who controls the money, data, and systems shaping our future? @1AkG connects Bitcoin, AI, health, and energy into a founder’s call to build with longer time horizons, stronger infrastructure, and greater agency at @TOtechweek

AI isn’t replacing clinical endpoints, but it is reshaping how we get there. Learn more about our approach at canurta.com/platform

This enables: • Faster insight into drug activity • Better patient stratification • More informed go/no-go decisions in early trials For emerging therapies, this shift could significantly accelerate development timelines while reducing cost and risk.

AI-derived biomarkers are gaining recognition as valid exploratory endpoints in drug development. An AI biomarker is a measurable biological signal identified or interpreted using artificial intelligence to detect patterns that may not be visible through traditional analysis.

Canurta Research Associate Kelly Boddington explains our process in this video. Learn more about our technology platform at canurta.com/platform

Those predictions are then validated through in vitro testing and model organisms, advancing step by step through preclinical development and toward clinical trials. From in silico discovery to real-world therapeutics, this is how we translate data into impact, faster.

It starts with a prediction. At Canurta, we use bioinformatics and computational models to identify and design novel molecules, accelerating the pace of discovery before they ever enter the lab.

SOVEREIGN 2026 is coming to @TOtechweek A one-day event exploring the intersection of human performance, decentralized finance, and AI. 📅 May 28, 2026 ⏰ 8:30 AM – 5:30 PM 📍 Downtown Toronto Register: luma.com/dbt71yy1

At Canurta, we’re tackling this complexity head-on, leveraging advanced science to identify and develop breakthrough botanical therapies that act across multiple biological pathways. It’s a harder path. But it’s the one that leads to meaningful outcomes.

Some of the most impactful diseases aren’t driven by a single target. They’re complex, multi-factorial, and require a different approach. That’s where multi-target therapies come in, as Canurta Research Associate Eric Soubeyrand explains.

Our multi-target compounds of interest may influence the following, all at once: Cytokine signaling, Oxidative stress networks, Interconnected inflammatory pathways We believe that chronic disease requires a network-level strategy. Learn more at Canurta.com/pipeline

Single-target drug design has limitations in network-driven diseases. Let's look at the numbers: • >90% of chronic diseases involve multiple biological pathways • 1 receptor is the focus of most legacy drug models • 100+ signaling interactions in inflammatory cascades

Canurta’s CNR-400 candidates target neurodegenerative diseases like ALS, Alzheimer’s, and FTD. View the research and join the open peer review here: researchhub.com/paper/11125246…

Using RNA sequencing of fly brains, researchers identified changes across biological pathways linked to neuronal signaling, lipid metabolism, inflammation, and cellular energy systems. The results suggest this formulation engages multiple biological networks simultaneously.

NEW PAPER: In complex diseases like ALS, where several cellular systems contribute to disease progression, understanding how molecules interact across pathways is a key step in therapeutic research.

Challenges: - Specialized extraction required - Low natural abundance - Pharmaceutical-grade scaling complexity Rare compounds require infrastructure, IP protection, and clinical discipline. We are proud of our IP-secured extraction and synthesis of cannflavins.

Cannflavins A & B — by the numbers: - First identified in 1985 - Demonstrated up to 30x more effective than aspirin at inhibiting mPGES-1 activity - 1 Plant genus known to produce cannflavins: Cannabis - 100% non-cannabinoid plant metabolites - 0 Psychoactive effects

Our story began with a breakthrough. In 2019, Canurta Advisor Dr. Tariq Akhtar’s lab at the University of Guelph developed a patented method to efficiently extract and enrich rare polyphenols like cannflavins A & B.